Controversies in the Management of Early-Stage Hodgkin Lymphoma
Patients with early-stage Hodgkin lymphoma (HL) often experience high cure rates with current therapeutic measures which include chemotherapy alone or chemotherapy and radiotherapy; however, late effects due to treatment-related toxicity is of significant concern. Emerging studies are shedding light on these controversies and clinicians are challenged to remain abreast of these developments to optimize treatment of patients with early-stage HL. 
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates in the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Sequencing Therapy and the Role of MRD Testing
There is a continuing need to educate hematologists and oncologists about the challenges and special considerations involved in the management of patients with CLL/SLL so that they can make informed clinical decisions and develop an individualized treatment plan for their patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment
Educating clinicians about the biology of MZLs, novel therapeutic approaches and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is it Time to Consider CAR T for All?
There is a clear need for clinicians to receive education regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of treatment-related adverse events and the effective management strategies. More importantly, clinicians should refer appropriate patients for participation in well-designed clinical studies to facilitate the development of CAR T-cell therapies. 
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Peripheral T-Cell Lymphomas-Not Otherwise Specified: A Shrinking Entity?
Peripheral T-cell lymphomas-not otherwise specified (PTCL-NOS) is now considered a heterogeneous group of distinct molecular subtypes with varied natural history and clinical outcome. Although the standard treatment approach remains the same for all subtypes of PTCL-NOS, these findings will have significant impact on the management of patients with PTCL-NOS as important evidence from clinical trials get translated into routine clinical practice.
Category
  • T-Cell Lymphomas
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Interactive Online Case Studies: Lymphoma - Case 1
Category
  • Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Interactive Online Case Studies: Lymphoma - Case 3
Category
  • Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Emerging Therapeutic Options in Acute Lymphoblastic Leukemia
With increased use of immunotherapies in ALL treatment, it is important for oncology care providers to be aware of the best ways to incorporate these therapies into standard practice. Additionally, continued education will allow oncology care providers to become very conversant with the unique side effects associated with immunotherapy, leading to the development of appropriate disease management strategies.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Advances in Acute Myeloid Leukemia (AML) Management: Focus on Secondary AML and Older Patients with AML
Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations. 
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Myeloproliferative Neoplasms: Emerging Treatment Options for Myelofibrosis
Appropriate symptom assessment is essential to develop an effective symptom-directed approach. Informing clinicians about the recent advances can help them develop an optimal treatment strategy with the incorporation of novel agents into the treatment plan based on the patient’s clinical needs.
Category
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages